Norris Perne & French LLP MI Sells 110,649 Shares of Charles River Laboratories International, Inc. $CRL

Norris Perne & French LLP MI lessened its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 92.0% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 9,673 shares of the medical research company’s stock after selling 110,649 shares during the period. Norris Perne & French LLP MI’s holdings in Charles River Laboratories International were worth $1,513,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Cromwell Holdings LLC lifted its holdings in shares of Charles River Laboratories International by 542.9% during the second quarter. Cromwell Holdings LLC now owns 180 shares of the medical research company’s stock worth $27,000 after buying an additional 152 shares during the last quarter. Neo Ivy Capital Management bought a new stake in shares of Charles River Laboratories International in the second quarter valued at about $29,000. Geneos Wealth Management Inc. grew its position in Charles River Laboratories International by 98.0% during the second quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock worth $44,000 after buying an additional 145 shares in the last quarter. Allworth Financial LP grew its position in Charles River Laboratories International by 172.7% during the second quarter. Allworth Financial LP now owns 300 shares of the medical research company’s stock worth $45,000 after buying an additional 190 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd bought a new position in Charles River Laboratories International during the second quarter valued at about $56,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock opened at $203.55 on Monday. The firm has a market capitalization of $10.02 billion, a P/E ratio of -130.48, a P/E/G ratio of 6.39 and a beta of 1.63. The stock has a fifty day moving average price of $182.85 and a two-hundred day moving average price of $167.67. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $204.47. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.37 and a quick ratio of 1.10.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, November 5th. The medical research company reported $2.43 EPS for the quarter, beating the consensus estimate of $2.32 by $0.11. Charles River Laboratories International had a negative net margin of 2.07% and a positive return on equity of 15.78%. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $990.43 million. During the same quarter in the previous year, the company earned $2.59 EPS. The firm’s revenue for the quarter was down .5% compared to the same quarter last year. As a group, analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

CRL has been the topic of several recent research reports. Mizuho lifted their price objective on Charles River Laboratories International from $174.00 to $200.00 and gave the stock a “neutral” rating in a report on Thursday, December 18th. Jefferies Financial Group raised Charles River Laboratories International from a “hold” rating to a “buy” rating and raised their target price for the stock from $142.00 to $195.00 in a research report on Tuesday, September 9th. Baird R W raised shares of Charles River Laboratories International from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 6th. Evercore ISI increased their price objective on shares of Charles River Laboratories International from $190.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, October 3rd. Finally, Morgan Stanley set a $185.00 price objective on shares of Charles River Laboratories International in a report on Monday, December 1st. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $195.93.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.